Advertisement
PCVX vs REGN
Which Stock Would AI Choose? Vaxcyte (PCVX) vs. Regeneron Pharmaceuticals (REGN) Stock Comparison
Key Takeaways
- PCVX is a clinical-stage biotechnology company focused on developing advanced conjugate vaccines for bacterial diseases, with a market capitalization of approximately $8.6 billion.
- REGN is an established biotechnology firm with a diversified portfolio of approved medicines and a market capitalization exceeding $70 billion, offering greater scale and revenue stability.
- In recent market activity, PCVX has demonstrated stronger year-to-date gains compared to REGN, reflecting investor interest in its vaccine pipeline progress.
- REGN maintains a more consistent performance profile with upcoming quarterly results scheduled for late July, while PCVX continues to navigate clinical development milestones typical of earlier-stage companies.
- Sector exposure for both centers on biotechnology, though PCVX carries higher volatility associated with clinical-stage assets, whereas REGN benefits from commercial products and broader diversification.
- Market sentiment highlights a contrast between growth-oriented momentum in PCVX and the relative stability observed in REGN amid broader healthcare sector dynamics.
Introduction
This comparison examines PCVX and REGN, two biotechnology stocks with distinct profiles in the healthcare sector. PCVX represents a clinical-stage innovator advancing vaccine candidates, while REGN operates as a more mature player with commercialized therapies. The analysis is relevant for traders and investors seeking to understand relative performance, risk profiles, and positioning within the biotechnology industry. It provides factual context on recent market behavior and key business attributes to support informed evaluation of these equities in the current environment.
PCVX Overview and Recent Performance
Vaxcyte, Inc. (PCVX) is a clinical-stage biotechnology company developing conjugate and protein-based vaccines targeting bacterial infectious diseases. Its pipeline emphasizes candidates such as VAX-24 and VAX-31 for pneumococcal disease prevention. In recent market activity, the stock has shown notable appreciation, with year-to-date returns exceeding 29 percent amid ongoing clinical advancements and a solid cash position reported in prior quarterly updates. Sentiment has been influenced by pipeline progress and broader investor appetite for innovative vaccine platforms, though the company remains subject to the inherent volatility of clinical-stage development. Market capitalization stands near $8.6 billion, reflecting its growth-oriented positioning.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company engaged in the discovery, development, and commercialization of medicines across multiple therapeutic areas. It maintains a portfolio of approved products alongside a pipeline of candidates. In recent market activity, the stock has posted more moderate year-to-date gains around 13 percent, supported by its established commercial presence. Upcoming second-quarter 2026 financial results, scheduled for release on July 30, represent a near-term catalyst. The company operates with a market capitalization above $70 billion, providing greater scale compared to earlier-stage peers. Sentiment reflects steady positioning within the biotechnology sector, tempered by periodic analyst target adjustments.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots from a broader collection of hundreds available on the platform. These bots trade thousands of different tickers and employ varied strategies, timeframes, and performance metrics tailored to current market conditions. Only those demonstrating strong suitability, consistency, and adaptability earn placement in the trending section, where users can review statistics such as win rates, profit factors, and drawdown ranges across different styles. All available AI trading bots differ in their approaches, risk parameters, and ticker focus, enabling customization for diverse trading objectives. For further details on these tools, visit the Trending AI Robots page.
Head-to-Head Comparison
PCVX and REGN operate in the biotechnology sector but differ markedly in maturity and business model. PCVX focuses on early-stage vaccine innovation with high potential upside tied to clinical success, while REGN leverages approved products for revenue generation and stability. Recent momentum favors PCVX in percentage terms, though REGN exhibits lower volatility. Risk factors for PCVX include development timelines and cash utilization, whereas REGN faces competition and regulatory considerations in its commercial portfolio. Market sentiment positions PCVX as a higher-growth opportunity with corresponding uncertainty, contrasting REGN’s emphasis on established operations and upcoming earnings visibility.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative stability, and positioning amid recent market activity, Tickeron’s AI would currently assign a probabilistic preference toward REGN due to its scale, diversified revenue base, and more predictable operational profile. PCVX demonstrates stronger short-term momentum but carries elevated volatility typical of clinical-stage assets. This assessment remains conditional on evolving data including clinical updates and earnings outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PCVX is a Buy and REGN is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PCVX’s FA Score shows that 0 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).
- PCVX’s FA Score: 0 green, 5 red.
- REGN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PCVX’s TA Score shows that 6 TA indicator(s) are bullish while REGN’s TA Score has 6 bullish TA indicator(s).
- PCVX’s TA Score: 6 bullish, 4 bearish.
- REGN’s TA Score: 6 bullish, 5 bearish.
Price Growth
PCVX (@Biotechnology) experienced а +0.12% price change this week, while REGN (@Biotechnology) price change was +2.04% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.21%. For the same industry, the average monthly price growth was +7.25%, and the average quarterly price growth was +1806.27%.
Reported Earning Dates
PCVX is expected to report earnings on Aug 12, 2026.
REGN is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Biotechnology (-3.21% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| PCVX | REGN | PCVX / REGN | |
| Capitalization | 8.24B | 69.5B | 12% |
| EBITDA | -1.06B | 5.75B | -19% |
| Gain YTD | 23.602 | -13.861 | -170% |
| P/E Ratio | N/A | 16.19 | - |
| Revenue | 0 | 14.9B | - |
| Total Cash | 1.74B | 8.75B | 20% |
| Total Debt | 116M | 2.71B | 4% |
PCVX | REGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 42 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 66 Overvalued | 2 Undervalued | |
PROFIT vs RISK RATING 1..100 | 76 | 86 | |
SMR RATING 1..100 | 98 | 60 | |
PRICE GROWTH RATING 1..100 | 40 | 53 | |
P/E GROWTH RATING 1..100 | 47 | 38 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (2) in the Biotechnology industry is somewhat better than the same rating for PCVX (66) in the null industry. This means that REGN’s stock grew somewhat faster than PCVX’s over the last 12 months.
PCVX's Profit vs Risk Rating (76) in the null industry is in the same range as REGN (86) in the Biotechnology industry. This means that PCVX’s stock grew similarly to REGN’s over the last 12 months.
REGN's SMR Rating (60) in the Biotechnology industry is somewhat better than the same rating for PCVX (98) in the null industry. This means that REGN’s stock grew somewhat faster than PCVX’s over the last 12 months.
PCVX's Price Growth Rating (40) in the null industry is in the same range as REGN (53) in the Biotechnology industry. This means that PCVX’s stock grew similarly to REGN’s over the last 12 months.
REGN's P/E Growth Rating (38) in the Biotechnology industry is in the same range as PCVX (47) in the null industry. This means that REGN’s stock grew similarly to PCVX’s over the last 12 months.
| PCVX | REGN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 71% | 1 day ago 48% |
| Stochastic ODDS (%) | 1 day ago 76% | 1 day ago 58% |
| Momentum ODDS (%) | 1 day ago 77% | 1 day ago 61% |
| MACD ODDS (%) | 1 day ago 81% | 5 days ago 72% |
| TrendWeek ODDS (%) | 1 day ago 76% | 1 day ago 63% |
| TrendMonth ODDS (%) | 1 day ago 76% | 1 day ago 62% |
| Advances ODDS (%) | 22 days ago 78% | 12 days ago 63% |
| Declines ODDS (%) | 1 day ago 71% | 1 day ago 55% |
| BollingerBands ODDS (%) | 1 day ago 83% | 1 day ago 53% |
| Aroon ODDS (%) | 1 day ago 82% | 1 day ago 64% |
Advertisement